It is very uncertain whether standard intravenous acetylcysteine regimen (20.5 hour) changes hepatotoxicity compared with shorter intravenous acetylcysteine regimen (12 hour) (very low certainty).
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics from 0‐2 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics 0‐12 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower anaphylactoid symptoms compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
It is very uncertain whether cyanoacrylate 1 mL changes re‐bleeding Bleeding after initial success in the intervention compared with cyanoacrylate 0.5 mL (very low certainty).
It is very uncertain whether cyanoacrylate 1 mL changes control of bleeding Success in control the active variceal bleeding compared with cyanoacrylate 0.5 mL (very low certainty).
It is very uncertain whether cyanoacrylate 1 mL changes total mortality Total deaths and the end of compared with cyanoacrylate 0.5 mL (very low certainty).
It is very uncertain whether cyanoacrylate 1 mL changes day ‐ mortality Mortality due to bleeding compared with cyanoacrylate 0.5 mL (very low certainty).
It is very uncertain whether cyanoacrylate 1 mL changes failure of intervention Continuous bleeding after intervention compared with cyanoacrylate 0.5 mL (very low certainty).
It is very uncertain whether cyanoacrylate 1 mL changes complications (fever) Presence of fever compared with cyanoacrylate 0.5 mL (very low certainty).